ECCO guidelines on inflammatory bowel disease and malignancies

Abstract

This guideline is the second European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on inflammatory bowel disease [IBD] and malignancy, and is an update on the guidance published in 2015. This edition was designed to address key areas in which the management of IBD may be affected by either the risk of or the presence of malignancy. These include the risk of cancers associated with IBD, the risk of cancers from therapies used to treat IBD, and the management of IBD in a patient with active or recent cancer. This guideline was created according to ECCO’s standardised methodology. A panel of 27 experts was selected by the ECCO Guidelines Committee from a competitive pool of applicants. Two guidelines committee members, HG and TR, were selected as project coordinators. Participating experts were split into four working groups [WG] and a leader was selected for each WG. Topics were determined by the project coordinators and WG leaders and split between the four groups as follows: WG1, IBD and risk of malignancy; WG2, Small molecules and malignancy in IBD; WG3, Biologics and malignancy in IBD; and WG4, Managing IBD in patients with a history of cancer.